Literature DB >> 16322604

The new Clostridium difficile--what does it mean?

John G Bartlett, Trish M Perl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16322604     DOI： 10.1056/NEJMe058221

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  36 in total

1.  In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.

Authors:  Anne-Marie Bourgault; François Lamothe; Vivian G Loo; Louise Poirier
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

3.  Assessment of severity of Clostridium difficile infection.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

4.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

5.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

Review 6.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

7.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

8.  Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein.

Authors:  Christian Hardt; Thomas Berns; Wolfgang Treder; Franz-Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

9.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

10.  Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms.

Authors:  Susan M Novak-Weekley; Elizabeth M Marlowe; John M Miller; Joven Cumpio; Jim H Nomura; Paula H Vance; Alice Weissfeld
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.